Skip to main content
. Author manuscript; available in PMC: 2018 Jun 11.
Published in final edited form as: Sci Transl Med. 2015 Sep 16;7(305):205ps20. doi: 10.1126/scitranslmed.aaa8280

Fig. 4. Measuring efficacy of disease-modifying strategies in PD.

Fig. 4

(A) Assessing disease modification versus symptomatic benefit using compound washout. Black line represents placebo, blue line represents a disease-modifying therapeutic, dashed light blue line represents a symptomatic therapeutic such as L-DOPA, red arrow represents a change in UPDRS. (B) Using time to initiation of symptomatic treatment as an end point in PD clinical trials. Black line represents placebo, blue line represents a disease-modifying therapeutic, red arrow represents the change in time required for the initiation of symptomatic treatment.